Mammary tumors are the most common cancer in unspayed female dogs, and roughly half of them turn out to be malignant. Most cases appear between ages 7 and 13, and certain breeds carry higher risk than others. The disease shares a surprising amount of biology with human breast cancer, which has made it both a serious veterinary concern and a valuable research model. But the picture is more nuanced than a simple “common cancer” label suggests, from the role of spaying to how tumor type shapes survival.
How Common Are Mammary Tumors, and Which Dogs Get Them
Mammary tumors show up overwhelmingly in female dogs, and intact (unspayed) females bear the greatest burden. In large registry-based studies, the peak incidence falls between roughly 8 and 13 years of age, with tumors becoming less common in dogs younger than 6.1PubMed. Incidence of mammary tumors in the canine population living in the Veneto region (Northeastern Italy): Risk factors and similarities to human breast cancer A Brazilian retrospective study of nearly 450 dogs with malignant mammary tumors found a mean age at diagnosis of about 10 years, with the largest cluster between 9 and 12 years old.2PubMed Central. Identifying the Risk Factors for Malignant Mammary Tumors in Dogs: A Retrospective Study
Small-breed dogs appear to be disproportionately affected. In that same study, small dogs made up about 59% of the malignant-tumor population, with medium dogs at 29% and large dogs at 12%, and body size was statistically linked to malignant diagnosis.3PubMed Central. Identifying the Risk Factors for Malignant Mammary Tumors in Dogs: A Retrospective Study Poodles were the single most represented breed, and they tended to be diagnosed at a slightly older age than other breeds. Italian registry data identified Samoyeds, Dobermanns, Schnauzers, and Yorkshire Terriers as breeds more prone to developing malignant mammary tumors, and purebred dogs in general had a higher probability of malignancy than mixed breeds, particularly when diagnosed before age 7.4PubMed. Incidence of mammary tumors in the canine population living in the Veneto region (Northeastern Italy): Risk factors and similarities to human breast cancer
Does Spaying Actually Prevent It
For decades, veterinary textbooks stated confidently that spaying a dog before her first heat cycle virtually eliminates the risk of mammary cancer. That claim has been widely repeated, and there is real biological logic behind it: mammary tumors in dogs are heavily hormone-driven, with many tumors expressing estrogen and progesterone receptors. Removing the ovaries removes the hormonal fuel.
But the evidence base is less airtight than most owners realize. A 2025 systematic review looked at the 13 studies that met reasonable quality standards and found that six of them reported no evidence of a protective effect from early spaying against mammary tumor development.5PubMed Central. Systematic Review: Does Pre-Pubertal Spaying Reduce the Risk of Canine Mammary Tumours? That does not mean spaying is useless. The remaining studies did find a protective effect, and the hormonal mechanism is well established. What it does mean is that the classic numbers often cited (like a 0.5% risk if spayed before the first heat) come from older, methodologically limited work, and more recent studies with stricter designs have produced mixed results. The honest answer is that spaying likely reduces the risk, but the degree of protection is less certain than veterinary tradition has implied.
The Role of Body Condition Early in Life
Obesity in adult dogs has not been clearly linked to mammary cancer in the same way it has in humans. A case-control study found that neither a high-fat diet nor being overweight a year before diagnosis raised the odds of breast cancer. But a striking pattern emerged when the researchers looked at body condition during puppyhood: among spayed dogs, those that had been thin at 9 to 12 months of age had a dramatically lower risk of later developing mammary cancer.6American Journal of Epidemiology. Body Conformation, Diet, and Risk of Breast Cancer in Pet Dogs: A Case-Control Study The effect was less clear in intact dogs, but the finding hints that early-life nutritional environment may shape mammary cancer risk, paralleling similar observations in human breast cancer epidemiology.
Benign Versus Malignant, and the Idea of Progression
When a veterinarian finds a mammary lump, the first practical question is whether it is benign or malignant. In large series, the split tends to be close to even. A study comparing classification systems across 305 mammary tumors found about 53% were benign and 47% malignant.7PubMed. Canine Mammary Tumors: Comparison of Classification and Grading Methods in a Survival Study Among malignant tumors, carcinomas (cancers arising from glandular tissue) dominate, accounting for the vast majority. Sarcomas (arising from connective tissue) are far less common. In one histopathological series, carcinomas made up about 87% of malignant mammary tumors, with simple carcinomas being the most frequent subtype.8PubMed Central. Classification and grading of canine malignant mammary tumors
An important observation is that mammary tumors in dogs appear to progress from benign to malignant over time. Dogs frequently develop multiple mammary tumors at once, and a study of 90 dogs with 236 tumors found that malignant tumors were significantly larger than benign ones (averaging about 4.7 cm versus 2.1 cm), that dogs with malignant tumors were older, and that histological evidence of progression increased with tumor size.9PubMed. Canine mammary gland tumours; a histological continuum from benign to malignant; clinical and histopathological evidence Dogs with malignant tumors were also more likely to develop new primary tumors. This progression pattern resembles what happens in human breast carcinogenesis, and it has practical implications: a benign lump today can become a malignant one if left alone long enough.
What Determines Prognosis
Not all malignant mammary tumors behave the same way, and veterinary oncologists look at several factors to gauge how aggressive a particular cancer is. Tumor size and histologic grade consistently emerge as the strongest independent predictors of survival. A study of 229 cases found that tumor diameter was a strong predictor of both metastasis and survival in multivariate analysis, while lymphatic invasion and grade predicted recurrence and spread in univariate analysis.10PubMed. Prognostic Significance of Canine Mammary Tumor Histologic Subtypes: An Observational Cohort Study of 229 Cases Bio-scoring systems developed for canine mammary carcinomas confirmed that tumor size and grade were the factors that held up when multiple variables were tested together.11PubMed. Developing and testing prognostic bio-scoring systems for canine mammary gland carcinomas
In practical terms, smaller tumors caught earlier tend to carry better outcomes. And grading, which looks at features like how quickly the tumor cells are dividing and how abnormal they look under a microscope, helps veterinary pathologists sort tumors into low, intermediate, and high-grade categories. High-grade tumors, with rapid cell division, are the ones most likely to spread.
Molecular Subtypes Mirror Human Breast Cancer
One of the most interesting developments in veterinary oncology is the realization that canine mammary tumors can be classified into molecular subtypes using the same framework applied to human breast cancer. Using markers for estrogen receptor, progesterone receptor, and the HER2 protein, researchers have identified luminal A, luminal B, HER2-positive, and triple-negative subtypes in dogs, just as in women.
A study of 110 canine mammary tumors classified 42 as luminal A, 41 as luminal B, 17 as triple-negative, and 10 as HER2-positive. The luminal subtypes (which express hormone receptors) carried a better prognosis, while HER2-positive and triple-negative tumors were more aggressive, with higher rates of metastasis and shorter survival.12PubMed Central. Prognostic phenotypic classification for canine mammary tumors HER2 overexpression specifically has been found in roughly 13 to 14% of canine mammary carcinomas at the highest staining intensity, with another third showing equivocal expression.13PubMed Central. HER2 Overexpression and Cytogenetical Patterns in Canine Mammary Carcinomas
These parallels have made the dog an increasingly important comparative model for human breast cancer research. Dogs develop mammary tumors spontaneously, live with their owners in shared environments, and show mutational profiles that overlap with those in human patients.14PubMed Central. Canine as a Comparative and Translational Model for Human Mammary Tumor Researchers have even built living biobanks of canine mammary tumor organoids (three-dimensional cell cultures) that may prove especially useful for studying estrogen-receptor-positive breast cancers, an area where standard mouse models have significant limitations.15Scientific Reports. A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer
The BRCA Connection
The genes most famously linked to human breast cancer, BRCA1 and BRCA2, also play a role in dogs. BRCA2 expression has been shown to be reduced in canine mammary tumor tissue, and specific variations in the BRCA2 gene can weaken the binding between the BRCA2 protein and its DNA-repair partner RAD51, undermining the cell’s ability to fix damaged DNA.16PubMed Central. Mutations of BRCA2 in canine mammary tumors and their targeting potential in clinical therapy A broader review of both BRCA1 and BRCA2 in canine cancers concluded that these genes influence the development and progression of canine tumors much as they do in people, though the area remains underexplored compared to human oncology.17PubMed Central. Exploring the Therapeutic Potential of BRCA1 and BRCA2 as Targets in Canine Oncology: A Comprehensive Review of Their Role in Cancer Development and Treatment As genetic testing becomes more affordable in veterinary medicine, BRCA status could eventually help guide treatment decisions, much as it does for human patients today.
Surgery Is the Primary Treatment
For most dogs diagnosed with a mammary tumor, surgery is the first-line treatment, and the extent of the operation matters. A retrospective study tracking survival across different surgical approaches found that dogs treated with lumpectomy (removing just the tumor) had the worst outcomes, with a median survival of about 103 days, compared to well over a thousand days for dogs receiving regional or unilateral mastectomy. Dogs undergoing lumpectomy were nearly five times more likely to die than those treated with more extensive surgery.18PubMed Central. Lumpectomy May Negatively Impact Survival in Female Dogs with Mammary Carcinomas
This does not mean every dog needs a radical bilateral mastectomy. The decision depends on how many glands are affected, the size and location of tumors, and the dog’s overall health. But the data suggest that removing a wider margin of tissue, whether through regional or unilateral mastectomy, gives the best chance at long-term survival. For dogs with tumors in multiple glands on one side, removing the entire mammary chain on that side is common practice.
Staging and Advanced Diagnostics
Beyond surgery, knowing whether the cancer has spread is critical. Veterinarians typically check regional lymph nodes, take chest X-rays to look for lung metastases, and may perform abdominal ultrasound. One emerging technique is computed tomographic indirect lymphography, which can identify whether cancer has reached the sentinel lymph node (the first node that drains the tumor). A prospective study found this method achieved about 93% sensitivity and 100% specificity when assessed one minute after contrast injection, supporting its use as a diagnostic tool for staging mammary cancer in dogs.19PubMed. Assessment of Sentinel Lymph Node Metastasis in Canine Mammary Gland Tumors Using Computed Tomographic Indirect Lymphography
On the less invasive side, circulating microRNAs in the blood may eventually serve as biomarkers. Two microRNAs, miR-19b and miR-125a, were significantly higher in dogs with mammary carcinoma, and both showed high accuracy in distinguishing cancer from non-cancer. A third, miR-18a, was elevated specifically in dogs whose tumors had invaded lymphatic vessels.20PubMed Central. Circulating microRNA as biomarkers of canine mammary carcinoma in dogs These blood-based markers are not yet routine in veterinary clinics, but they hint at a future where a simple blood draw could help catch mammary cancer earlier or monitor response to treatment.
Chemotherapy and Emerging Drug Targets
Chemotherapy is generally reserved for dogs with aggressive, high-grade, or metastatic mammary carcinomas. One study examined adding low-dose naltrexone to carboplatin chemotherapy after mastectomy and found that dogs receiving the combination had notably longer average observation times (about 526 days) compared to chemotherapy alone (about 200 days) or mastectomy alone (about 123 days), with improved quality of life.21PLOS ONE. The effect of naltrexone as a carboplatin chemotherapy-associated drug on the immune response, quality of life and survival of dogs with mammary carcinoma
Meanwhile, several targeted drugs already used in human oncology are being tested in canine mammary cancer cells. Lab studies have shown that palbociclib (a CDK4/6 inhibitor used in human luminal breast cancer) slows proliferation in canine mammary cancer cell lines in a dose-dependent way. Alpelisib, which targets PIK3CA mutations, triggers cell death in canine cells carrying that mutation. And everolimus, an mTOR inhibitor, reduces key growth signals in canine mammary tumor cells.22PubMed Central. Mapping the Kinase Inhibitor Landscape in Canine Mammary Carcinoma: Current Status and Future Opportunities These are still largely in vitro results, meaning they work in the lab but clinical trials in actual dogs are limited. Still, the shared molecular biology between canine and human mammary tumors means that as human targeted therapies mature, canine patients may benefit as well.
Inflammatory Mammary Carcinoma
The most feared form of mammary cancer in dogs is inflammatory mammary carcinoma, a rare and highly aggressive variant. It looks different from a typical mammary lump: the affected skin is warm, swollen, painful, and often resembles a severe infection more than a tumor. It spreads rapidly, and conventional chemotherapy has historically been ineffective. In a study of 12 dogs, those treated with doxorubicin-based chemotherapy survived a median of just 7 days after treatment, while dogs treated with piroxicam (a common anti-inflammatory drug) achieved a median survival of 185 days, with improvement in clinical condition.23PubMed Central. Inflammatory mammary carcinoma in 12 dogs: clinical features, cyclooxygenase-2 expression, and response to piroxicam treatment
A later study explored combining anti-angiogenic drugs (toceranib, piroxicam, and thalidomide) with or without radiation therapy. Dogs that received both medical therapy and radiation had substantially longer time to progression (156 days) and survival (180 days) compared to medical therapy alone (28 days to progression, 59 days survival).24PubMed. The impact of toceranib, piroxicam and thalidomide with or without hypofractionated radiation therapy on clinical outcome in dogs with inflammatory mammary carcinoma The numbers remain sobering, but the combination approach offers meaningful palliation and time for an otherwise rapidly fatal disease.
The Immune Landscape and Immunotherapy Prospects
Immunotherapy has transformed certain human cancers, and researchers are now mapping the immune landscape of canine mammary tumors to see whether similar strategies could work in dogs. The results are intriguing but somewhat counterintuitive. A study of 92 mammary tumors found that about 72% expressed PD-L1, the protein targeted by checkpoint inhibitor drugs in humans. Unexpectedly, dogs with PD-L1-negative tumors had shorter survival, while PD-L1-positive tumors were associated with higher counts of cancer-fighting immune cells and earlier clinical stage. On the other hand, higher numbers of regulatory T cells within tumors predicted shorter survival.25PubMed. PD-L1 expression and tumor-infiltrating T lymphocytes as prognostic factors in canine mammary tumors
Another immune checkpoint molecule, VISTA, has been identified in canine mammary tumors for the first time in a pilot study. VISTA expression in tumor cells increased with higher tumor grade, positioning it as a potential target for future immunotherapy as well as a prognostic marker.26PubMed. Immunohistochemical profiling of VISTA expression in canine mammary tumors: A pilot study for immunotherapeutic targeting No checkpoint inhibitor drugs are yet approved for use in dogs, but the groundwork for developing them is actively being laid.
Male Dogs Can Get It Too
Mammary tumors in male dogs are extremely rare but not impossible. A 24-year review of over 2,100 mammary neoplasms found just four cases in males, accounting for 0.18% of the total. Three of those four tumors were malignant, and two of the affected dogs also had concurrent testicular tumors. All of the malignant tumors in these males showed high expression of hormone receptors, suggesting that abnormal hormone exposure plays a role even in male cases.27PubMed. Mammary neoplasms in male dogs: A 24-year descriptive study
A broader review pooling data from 74 affected male dogs painted a somewhat different picture, finding that the majority of mammary tumors in males were actually benign (about 54%), with adenomas being the most common type. These occurred predominantly in the rear mammary glands and peaked around age 11. Crossbreeds, Cocker Spaniels, and German Shepherds were most frequently represented.28PubMed Central. Occurrence of mammary gland tumours in male dogs and its weak association with development of testicular tumours: a review An earlier retrospective study of 8 male dogs similarly found mostly benign tumors and noted that female dogs were 62 times more likely to develop mammary tumors than males.29Journal of Veterinary Internal Medicine. Mammary Gland Tumors in Male Dogs For male dogs, the takeaway is that any mammary lump warrants veterinary attention, but the prognosis after surgery alone is usually good.
Why Dogs Matter for Human Breast Cancer Research
The overlap between canine mammary tumors and human breast cancer goes beyond shared molecular subtypes. Dogs develop these tumors spontaneously, without the genetic engineering used in lab mice. They live in the same homes as their owners, breathe the same air, eat food contaminated with the same environmental pollutants, and age on a compressed timeline that allows researchers to observe disease progression over months rather than decades. Their tumors share mutational profiles, subtype classifications, treatment responses, and patterns of metastasis with human breast cancers.30PubMed Central. Canine as a Comparative and Translational Model for Human Mammary Tumor
This has practical consequences for both species. Clinical trials in dogs can move faster than human trials, providing early signals about which drugs work. And the fact that roughly two-thirds of human breast cancers are estrogen-receptor-positive, a subtype poorly modeled by mice, makes estrogen-receptor-positive canine mammary tumors especially valuable for preclinical work.31Scientific Reports. A living biobank of canine mammary tumor organoids as a comparative model for human breast cancer For dog owners, the silver lining of this common cancer is that advances in understanding it benefit both species. Every mammary tumor that gets properly characterized in a veterinary pathology lab adds to a shared knowledge base that feeds back into human oncology and, in turn, into better treatments for the next dog diagnosed.